28th week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110171133 | RADIOLABELLED MMP SELECTIVE COMPOUNDS - The invention is directed to radiolabelled MMP selective compounds, a processes for the preparation thereof, and uses thereof. The derivatives of the invention have formula (I) wherein Y represents O, CH | 2011-07-14 |
20110171134 | (6S)-5-METHYLTETRAHYDROFOLIC ACID FOR THERAPY OF TISSUE INJURY - The present invention relates generally to the field of methods useful in treating tissue injury. More specifically, the present invention relates to (6S)-5-methyltetrahydrofolic acid compounds, and methods of using the (6S)-5-methyltetrahydrofolic acid compounds, to treat conditions associated with nervous system injury. | 2011-07-14 |
20110171135 | PEST-CONTROL COMPOSITIONS AND METHODS HAVING HIGH TARGET AND LOW NON-TARGET ACTIVITY - Embodiments of the invention relate to compositions and methods for selective pest control wherein the compositions include active agents that in combination have a first activity against a selected target pest and a second activity against a selected non-target organism and wherein the first activity is greater than the second. Further embodiments of the invention relate to a method for developing selective pest control compositions and low-resistance pest control compositions. | 2011-07-14 |
20110171136 | OPTICAL IMAGING PROBES - This invention relates to optical imaging probes and the use of such probes for diagnosing and monitoring disease, and disease treatment. The optical imaging probes of the current invention can be used to identify and characterize normal and diseased tissues with regards to altered metabolic activity. | 2011-07-14 |
20110171137 | NOVEL NANOSTRUCTURES AND PROCESS OF PREPARING SAME - A process of preparing a plurality of nanostructures, each being composed of at least one target material is disclosed. The process comprises sequentially electrodepositing a first material and the at least one target material into pores of a porous membrane having a nanometric pore diameter, to thereby obtain within the pores nanometric rods, each of the nanometric rods having a plurality of segments where any two adjacent segments are made of different materials. The process further comprises and etching the membrane and the first material, thereby obtaining the nanostructures. | 2011-07-14 |
20110171138 | SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF - Provided herein is a highly pure deferasirox or a pharmaceutically acceptable salt thereof substantially free of hydrazine impurity, 4-hydrazinobenzoic acid, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure deferasirox or a pharmaceutically acceptable salt thereof substantially free of hydrazine impurity. | 2011-07-14 |
20110171139 | FASUDIL IN COMBINATION THERAPIES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT | 2011-07-14 |
20110171140 | ABSORPTION OF THERAPEUTIC AGENTS ACROSS MUCOSAL MEMBRANES OR THE SKIN - Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol. | 2011-07-14 |
20110171141 | ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE PARTICLES USING A METERED DOSE INHALER - Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90<5.0 micron volumetric median diameter. | 2011-07-14 |
20110171142 | Metformin glycinate salt for blood glucose control - The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride. | 2011-07-14 |
20110171143 | Method of maintaining oral health in animals - Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a disease caused by oral bacteria in an animal wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholiπo ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or a pharmaceutically acceptable salt thereof. | 2011-07-14 |
20110171144 | Functional Micelles for Hard Tissue Targeted Delivery of Chemicals - Compositions and methods for targeting agents to hard tissue are provided comprising A method includes administering to a subject a composition compπsing micelles, the micelles compπsing at least one amphiphilic block copolymer linked to at least one tooth targeting moiety The composition further includes at least one encapsulated compound and is provided in a pharmaceutically acceptable carrier. | 2011-07-14 |
20110171145 | Tooth whitener and stain remover - An inventive method resulting in a tooth whitening composition which solves daily regular facial and interproximal tooth staining and long term tooth color degradation; freshens breath due to minor halitosis; creates the appearance of brighter teeth, by way of its unique formulation, without changing tooth shade establishing tooth surface light refraction allowing the user with stained teeth to achieve immediate appearance of a brighter smile while the oxidizing formulation removes enamel staining and lightens the shade of the tooth enamel with regular use; gives user who may be sensitive to bleaching systems containing high levels of hydrogen peroxide a low dose alternative to prevent enamel and dentin tubual sensitivity; allows patients who have received prescription level bleaching at a dental office to regularly maintain the shade of their dentition for longer periods between retreatment at a dental office; and dispensed in a unique, convenient delivery system. | 2011-07-14 |
20110171146 | Anti-Aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods Of Use Thereof - An anti-aging composition comprising a skin-beneficial amount of actives identified in | 2011-07-14 |
20110171147 | Method for the Production of Unsaturated Alpha, Omega Dicarboxylic Acids and/or Unsaturated Alpha, Omega Dicarboxylic Diesters - The invention relates to a method for the production of unsaturated alpha,omega-dicarboxylic acids and/or their corresponding diesters, by reacting unsaturated carboxylic acids and/or their corresponding esters under the influence of specific ruthenium complex catalysts. The unsaturated alpha,omega-dicarboxylic acids and/or alpha,omega-dicarboxylic acid diesters obtained by the method are useful as UV filters in cosmetic sun screen preparations. | 2011-07-14 |
20110171148 | Sunscreen Composition - A composition contains at least one sunscreen and a protein-PVP copolymer. The sunscreen may be organic and/or inorganic, particularly titanium dioxide. The protein-PVP copolymer improves the effectiveness of the sunscreen, resulting in increased SPF values of the composition. | 2011-07-14 |
20110171149 | Skin Lightening Compositions - Compositions and methods for lightening and/or depigmenting skin are provided, the compositions comprising compounds having the structure: | 2011-07-14 |
20110171150 | MONOESTER OF N-UNDECYLENOYL PHENYLALANINE AND POLYOL, METHOD FOR PREPARING SAME, AND USE OF SAID ESTERS AS A SKIN LIGHTENING AGENT - A compound of the formula (I): | 2011-07-14 |
20110171151 | COSMETIC COMPOSITION CONTAINING A POLYMER COMPRISING A CARBOSILOXANE DENDRIMER UNIT - A cosmetic composition for making up and/or caring for the skin, containing a physiologically acceptable medium containing at least one vinyl polymer having at least one carbosiloxane-dendrimer-derived unit and at least 2% by weight of a silica, relative to the total weight of the composition, the ratio by weight between said polymer and said silica being greater than or equal to 1. | 2011-07-14 |
20110171152 | High Shine, Stick-Shaped Cosmetic Products - The present invention provides a cosmetic composition having a gloss of at least about 85 gloss units (gu), as well as sufficient shape retention properties for forming a stick-shaped cosmetic product. Specifically, the cosmetic composition contains: (a) a high viscosity oil component; (b) a medium viscosity oil component; (c) a low viscosity oil component; and (d) an oily gelling agent comprising an ester of glycerol or polyglycerin with an aliphatic or hydroxyl aliphatic acid and a dibasic acid. A stick-shaped cosmetic product formed by the cosmetic composition of the present invention exhibits a high-shine that is not available in conventional stick-shaped cosmetic products and yet retains the high make-up coverage typically provided by conventional stick-shaped cosmetic products. | 2011-07-14 |
20110171153 | TREATMENT OF KERATIN FIBRES WITH VOLATILE LINEAR ALKANE(S), SOLID FATTY ALCOHOL(S) AND POLYMERIC THICKENER(S) CONTAINING SUGAR UNITS - The invention relates to the use for the cosmetic treatment of keratin fibres, such as the hair, of a cosmetic composition comprising, in a cosmetically acceptable medium, more than 1% by weight, relative to the total weight of the composition, of one or more volatile linear alkanes, at least one solid fatty alcohol and at least one polymeric thickener containing sugar units. | 2011-07-14 |
20110171154 | ADDITIVE FOR HAIR COSMETIC PREPARATION, HAIR COSMETIC PREPARATION, AND METHOD FOR PRODUCING ADDITIVE FOR HAIR COSMETIC PREPARATION - The present invention provides an additive for a hair cosmetic preparation and a hair cosmetic preparation containing the additive that can give a supple feel to the finished hair. The additive for a hair cosmetic preparation contains a graft copolymer obtainable by graft-copolymerizing a cationic water-soluble monomer and a nonionic water-soluble monomer in an aqueous solution containing either one or both of a natural polymer and a natural polymer derivative that have an OH group. | 2011-07-14 |
20110171155 | Intermediates And Surfactants useful In Household Cleaning And Personal Care Compositions, And Methods Of Making The Same - Disclosed herein are novel mixtures of scattered-branched chain fatty acids and derivatives of scattered-branched chain fatty acids. Further disclosed are uses of these mixtures in cleaning compositions (e.g., dishcare, laundry, hard surface cleaners,) and/or personal care compositions (e.g., skin cleansers, shampoo, hair conditioners). | 2011-07-14 |
20110171156 | Topical Scar Treatment Composition - An anhydrous topical scar treatment product having a water activity of less than 0.50, the product being comprised of (i) a silicone elastomer, (ii) a non-volatile, anhydrous carrier vehicle, (iii) L-ascorbic acid in the form of fine powder, at a concentration of concentration of from 7.5% to 15% by weight, based on the total weight of the anhydrous topical scar treatment product, and (iv) an oil-soluble Vitamin C derivative at a concentration of from 5% to 10% by weight, based on the total weight of the anhydrous topical scar treatment product. | 2011-07-14 |
20110171157 | NON-SPHERICAL FINE PARTICLES, METHOD OF PRODUCTION THEREOF AND COSMETIC MATERIALS AND RESIN COMPOSITIONS CONTAINING SAME - Non-spherical fine particles capable of responding to highly advanced requirements of recent years, including further improvements in optical characteristics such as total light transmittance and optical diffusible property related to resin molded products and further improvements in feeling, soft focus, coverage and durability related to cosmetic products, as well as methods of their production and their use are provided. These non-spherical fine particles each have a polyhedral general shape with six or more surfaces each of which is formed as a concave surface, satisfying all of the conditions that the average value of the maximum external diameters L | 2011-07-14 |
20110171158 | ANTIMICROBIAL AND ANTIFOULING POLYMERIC MATERIALS - A polymeric material, methods of making the polymeric material, articles that include the polymeric material, and compositions that contain the polymeric material are provided. The polymeric material has a plurality of different pendant groups that include a first pendant group containing a —COOH group or a salt thereof, a second pendant group containing a poly(alkylene oxide) group, a third pendant group containing a silicon-containing group, and a fourth pendant group containing a quaternary amino group. The polymeric material can be used, for example, to provide coatings that can be antifouling, antimicrobial, or both. | 2011-07-14 |
20110171159 | Glycoside Derivatives and Uses Thereof - This invention relates to compounds represented by formula (I): | 2011-07-14 |
20110171160 | POLYMER CONJUGATES OF KISS1 PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-07-14 |
20110171161 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES - The invention provides protegrin that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention has enhanced half-life and/or reduced clearance. | 2011-07-14 |
20110171162 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-07-14 |
20110171163 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-07-14 |
20110171164 | POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-07-14 |
20110171166 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES - The invention provides osteocalcin that is chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer. | 2011-07-14 |
20110171167 | Isocyanate-Based Compositions and Their Use - The present disclosure describes a method and a kit for bulking, augmenting or occluding a tissue comprising administering a sufficient amount of a composition containing a biocompatible, non-bioabsorbable isocyanate-based material onto or into tissue. | 2011-07-14 |
20110171168 | HUMAN G-CSF ANALOGS AND METHODS OF MAKING AND USING THEREOF - An analog of human granulocyte colony stimulating factor (hG-CSF analog) is disclosed. The hG-CSF analog comprises an amino acid sequence that differs from the wild-type hG-CSF sequence at position 17 and at least one other position, and is capable of preventing trophoblast cell apoptosis. Also disclosed is pharmaceutical compositions comprising the hG-CSF analog, polynucleotides encoding the hG-CSF analog, expression vectors containing the polynucleotides, host cells containing the expression vectors, as well as a method for preventing spontaneous abortion using the hG-CSF analog. | 2011-07-14 |
20110171169 | PEPTIDES FOR ACTIVE ANTI-CYTOKINE IMMUNIZATION - Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angstroms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient. | 2011-07-14 |
20110171170 | CYTOTOXIC T CELL DEFINED EGFR PEPTIDE AND AN OPTIMIZED DERIVATIVE PEPTIDE - The invention provides a polypeptide having a sequence of amino acids consisting of IXDFGLAKL (SEQ ID NO: 1), as well as a nucleic acid encoding the polypeptide, vector comprising the nucleic acid, cell comprising the vector, and compositions thereof. The invention also provides a method of inducing a T-cell response in a patient with epithelial cancer, and a method inhibiting epithelial cancer, wherein the methods comprise administering the composition of the invention. The invention further provides a method of stimulating a cell with the inventive polypeptide and a cell so stimulated. | 2011-07-14 |
20110171171 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS - A compound of Formula 1.1A: 1.1A or salt thereof, as well as methods of making compounds of Formula 1.1A, methods of using compounds of Formula 1.1A to treat proliferative disorders such as cancer, and related compounds, composition, and methods. | 2011-07-14 |
20110171172 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein R | 2011-07-14 |
20110171173 | IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES - A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions. | 2011-07-14 |
20110171174 | Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside - The present invention relates to a synergistic combination of the compound of formula I: | 2011-07-14 |
20110171175 | INHIBITORS OF SERINE PROTEASES - This invention relates to compounds of formula I: | 2011-07-14 |
20110171176 | COMPLEMENT ANTAGONISTS AND USES THEREOF - Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug. | 2011-07-14 |
20110171177 | Compositions and Methods for Inhibiting Entry of a Hepatic Virus - The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection. | 2011-07-14 |
20110171178 | COMPOSITIONS AND METHODS OF USING PROISLET PEPTIDES AND ANALOGS THEREOF - Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof. | 2011-07-14 |
20110171179 | Method for Regulating Production of Hemoglobin Beta Chains - A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer. | 2011-07-14 |
20110171180 | BIOENGINEERED SKIN SUBSTITUTES - A bioengineered skin substitute was developed that contains a microfabricated basal lamina analog that recapitulates the native microenvironment found at the dermal-epidermal junction (DEJ). | 2011-07-14 |
20110171181 | METHODS FOR MODIFYING VASCULAR VESSEL WALLS - This invention relates in one aspect to the treatment of a vascular vessel with a biomaterial. The biomaterial can be a remodelable material that strengthens and/or supports the vessel walls. Additionally the biomaterial can include a variety of naturally occurring or added bioactive agents and/or viable cellular populations. | 2011-07-14 |
20110171182 | METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described. | 2011-07-14 |
20110171183 | Markers of Induced Pluripotent Stem Cells - The disclosure relates to the expression of podocalyxin-like protein (PODXL) on the surface of induced pluripotent stem cells and particularly, although not exclusively, to the use of PODXL as a marker of induced pluripotent stem cells. | 2011-07-14 |
20110171184 | Method for Introducing a Pna Molecule Conjugated to a Positively Charged Peptide into the Cytosol and/or the Nucleus by Photochemical Internalisation (Pci) - The present application relates to a method for introducing a PNA molecule into the cytosol, preferably the nucleus of a cell, comprising contacting said cell with a PNA molecule and a photosensitising agent, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said PNA molecule is conjugated to a positively charged peptide. Compositions comprising such conjugated PNA molecules, cells made using the method and uses of the method are also described. | 2011-07-14 |
20110171185 | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof - The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells. | 2011-07-14 |
20110171186 | CHONDROCYTE THERAPEUTIC DELIVERY SYSTEM - Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes. | 2011-07-14 |
20110171187 | DIETARY SUPPLEMENTS FOR PROMOTION OF GROWTH, REPAIR, AND MAINTENANCE OF BONE AND JOINTS - The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent. | 2011-07-14 |
20110171188 | NON-THERMAL PLASMA FOR WOUND TREATMENT AND ASSOCIATED APPARATUS AND METHOD - The invention relates to a non-thermal plasma for treatment of a surface, particularly for the treatment of a wound ( | 2011-07-14 |
20110171189 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 2011-07-14 |
20110171190 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2011-07-14 |
20110171191 | SUPPRESSION OF NEUROENDOCRINE DISEASES - The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptora melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion—from said tumourcell. The present invention also relates to polypeptides and nucleic acids for use in said methods. | 2011-07-14 |
20110171192 | SUBSTITUTED AMINE DERIVATIVE AND MEDICINAL COMPOSITION COMPRISING SAME AS THE ACTIVE INGREDIENT - A compound represented by following general formula (I): | 2011-07-14 |
20110171193 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - Provided herein are methods and materials for treating pulmonary hypertension (PH) in a subject. Also provided herein is a method of diagnosing whether a has PH by detecting a PH marker. A PKG pulmonary hypertension marker has been identified and may be useful in predicting PH disease progression and assessing a subject's response to PH therapy. | 2011-07-14 |
20110171194 | METHODS AND COMPOSITIONS FOR INHIBITING ABAD/ABeta PROTEIN INTERACTION - This invention provides methods, compositions and articles of manufacture for inhibiting binding between Aβ protein and ABAD in cells. Uses of this invention include, for example, treating Alzheimer's disease; reducing free radical generation, DNA fragmentation, and cytochrome C release in cells; and preserving cell viability by preventing LDH release from a cell. | 2011-07-14 |
20110171196 | METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN - The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension. | 2011-07-14 |
20110171197 | PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND COMPOSITIONS AND METHODS UTILIZING SAME - Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes. | 2011-07-14 |
20110171198 | HIGHLY FUNCTIONAL ENZYME HAVING ALPHA-GALACTOSIDASE ACTIVITY - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 2011-07-14 |
20110171199 | METHOD FOR REDUCING OR ELIMINATING PAIN ASSOCIATED WITH A POST-OPERATIVE WOUND - The present invention relates to methods for ameliorating or preventing pain associated with a post-operative wound and kits related thereto. The method comprises administering to the wound an effective amount of an anti-clotting agent solution and administration of an effective amount of an analgesic mixture solution comprising a fast-acting analgesic and a slower-acting analgesic. | 2011-07-14 |
20110171200 | PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND - Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rs1799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. Also provided are methods of treating subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype. | 2011-07-14 |
20110171201 | Formulation for Oral Administration of Proteins - Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant. | 2011-07-14 |
20110171202 | METHOD OF TREATING HEARING LOSS USING XIAP - Disclosed is a method of treating or preventing hearing loss in a subject. The method comprises administering to the subject in need thereof, an adeno-associated viral expression vector encoding X-linked inhibitor of apoptosis protein (XIAP). The XIAP is positioned in the vector for expression in an inner ear organ, or associated neural structures, of the subject so as to treat or prevent the hearing loss. Also disclosed is a method of treating or preventing impaired balance. | 2011-07-14 |
20110171203 | METHODS FOR TREATING NEOPLASTIC DISEASE TARGETING O-LINKED N-ACETYLGLUCOSAMINE MODIFICATIONS OF CELLULAR PROTEIN - Methods for treating a neoplastic disease in a mammalian subject are provided. The method provides administering an inhibitor of O-GlcNAc transferase in an amount effective to reduce or eliminate the neoplastic disease in the mammalian subject. Method for diagnosing a risk factor for a neoplastic disease in a mammalian subject and methods for identifying a test compound which inhibits a hexosamine signaling pathway in a cell or tissue are provided. | 2011-07-14 |
20110171204 | ANTIBODIES TO NTB-A - Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A. | 2011-07-14 |
20110171205 | NOVEL 15571, 2465, 14266, 2882, 52871, 8203 AND 16852 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 2011-07-14 |
20110171206 | ANTIBODY COMBINATIONS AND USE OF SAME FOR TREATING CANCER - A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings. | 2011-07-14 |
20110171207 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND AUTO-IMMUNE DISEASES - Compositions containing soluble B7-H4 (sH4) antagonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders are provided. Soluble H4 has been discovered to interfere with B7-H4 activity including B7-H4's activity as an inhibitor of T cell immunity. Thus, interference of sH4 biological activity is an effective method to restore B7-H4 activity and thereby provide an effective method for treating inflammatory diseases or disorders including autoimmune diseases or disorders. | 2011-07-14 |
20110171208 | CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF - The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases. | 2011-07-14 |
20110171209 | Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9 - The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases. | 2011-07-14 |
20110171210 | HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE - The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells. | 2011-07-14 |
20110171211 | HEAT SHOCK PROTEIN GP96 VACCINATION AND METHODS OF USING SAME - The invention provides a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a heat shock protein (hsp) gp96 polypeptide. The invention also provides a method of stimulating an immune response to a tumor by administering a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a gp96 polypeptide. | 2011-07-14 |
20110171212 | METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS - Disclosed are methods of minimizing the risk for a patient of developing pneumonitis during radiotherapy for a thorax-associated neoplasm and compositions for use in such methods. A preferred composition comprises a CD95/CD95L inhibitor. Further disclosed is a method of increasing the radiation dose administered to a patient during radiotherapy for a thorax-associated neoplasm. | 2011-07-14 |
20110171213 | METHODS FOR TREATING PANCREATIC CANCER - The present disclosure is directed to methods of treating pancreatic cancer in subject using cancer with antibodies that specifically bind to progastrin. | 2011-07-14 |
20110171214 | EFFICIENT WELL BEING ASSESSMENT AND IMPROVED TREATMENT PROTOCOL - Methods to appraise general health and to assess the effectiveness of therapeutic agents are disclosed. These methods can be performed on blood samples or other bodily fluids and comprise effecting cell death of endothelial cells, staining the dead cells and observing them microscopically. In addition, the invention is directed to combination treatments for neoplastic diseases or other conditions characterized by unwanted angiogenesis by administering an antiangiogenesis agent while maintaining nontoxic levels of ethanol and/or DMSO in the blood. | 2011-07-14 |
20110171215 | PD-1 SPECIFIC ANTIBODIES AND USES THEREOF - One aspect of the present disclosure provides antibodies that can act as agonists of PD-1, thereby modulating immune responses regulated by PD-1. Another aspect of the disclosure provides compositions comprising PD-1 specific antibodies and their use in methods of down regulating the immune response. These methods can be practiced on any subject, including humans or animals. Anti-PD-1 antibodies disclosed herein may be used, in another aspect of the invention, to detect PD-1 or its fragments in a biological sample. The amount of PD-1 detected may be correlated with the expression level of PD-1, and associated with the activation status of immune cells (e.g., activated T cells, B cells, and/or monocytes) in the subject. | 2011-07-14 |
20110171216 | MONOCLONAL ANTIBODIES SPECIFIC FOR PANCREATIC NEOPLASIA CELLS - Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic cancer cells or precancerous pancreatic cancer cells. Humanized forms of these antibodies, functional fragments of these antibodies, and hybridomas producing these antibodies are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. The antibodies can be used for in vitro or in vivo pancreatic cancer diagnosis or disease monitoring via detection of pancreatic cancer cells or the pancreatic cancer cell surface antigen. Methods of treating a pancreatic cancer by administration of the antibodies are also disclosed. | 2011-07-14 |
20110171217 | STABLE LIQUID ANTIBODY FORMULATION - The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanised anti-NGF antibody. | 2011-07-14 |
20110171218 | COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE - Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites. | 2011-07-14 |
20110171219 | TREATING CANCER STEM CELLS USING TARGETED CARGO PROTEINS - The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer. | 2011-07-14 |
20110171220 | PD-1 SPECIFIC ANTIBODIES AND USES THEREOF - One aspect of the present disclosure provides antibodies that can act as agonists of PD-1, thereby modulating immune responses regulated by PD-1. Another aspect of the disclosure provides compositions comprising PD-1 specific antibodies and their use in methods of down regulating the immune response. These methods can be practiced on any subject, including humans or animals. Anti-PD-1 antibodies disclosed herein may be used, in another aspect of the invention, to detect PD-1 or its fragments in a biological sample. The amount of PD-1 detected may be correlated with the expression level of PD-1, and associated with the activation status of immune cells (e.g., activated T cells, B cells, and/or monocytes) in the subject. | 2011-07-14 |
20110171221 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A NEOPLASIA - Compositions and methods for the diagnosis, treatment and prevention of cancer, including prostate cancer and renal cell carcinoma, as well as for treatment selection. | 2011-07-14 |
20110171222 | ANTI-HER3 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2011-07-14 |
20110171223 | Anti-peptide antibodies that cross react with protective antigen of bacillus anthracis and uses thereof - The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody. | 2011-07-14 |
20110171224 | PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION - Disclosed are pharmaceutical compositions that include a PsrP polypeptide, a nucleic acid encoding a PsrP polypeptide, or an antibody or fragment thereof that binds to a PsrP polypeptide domain, and methods of inhibiting, modulating, treating, or preventing a bacterial infection, such as an infection due to | 2011-07-14 |
20110171225 | Novel Plasmodium Falciparum Gene Encoding Signal Peptide Peptidase and Method of Using Inhibitors Thereof for Inhibiting Malarial Infection - This invention provides reagents, methods and pharmaceutical compositions for treating and preventing malaria. Specifically, the invention provides methods for inhibiting a | 2011-07-14 |
20110171226 | Novel Subtype of Closteridium Botulinum Neurotoxin Type A and Uses Thereof - A novel subtype of type A botulinum neurotoxin (BoNT/A) is disclosed in the application. Methods to purify the neurotoxin as well as uses thereof are also disclosed. | 2011-07-14 |
20110171227 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN DISORDERS - The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNFα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. | 2011-07-14 |
20110171228 | Methods and Compositions Relating to the Regulation of Apoptosis by MUC1 and BH3-Containing Proapoptotic Proteins - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or immune cell growth. The invention provides methods of inhibiting interactions between MUC1 and BH3-containing proapoptotic proteins, methods of inhibiting MUC1 expression, and methods of promoting apoptosis. Also provided are screening methods for compounds that inhibit interactions between MUC1 and BH3-containing proapoptotic proteins and pharmaceutical compositions of the same. | 2011-07-14 |
20110171229 | MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST CARCINOMA - It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein. | 2011-07-14 |
20110171230 | Method of Identifying Agents that Promote Axonal Development - The present invention is based on the discovery of a novel function of an FKBP proline isomerases in chemotropic nerve guidance and axon regeneration through gating of TRPC1 channel activity. Accordingly, there are provided methods for identifying an agent that inhibits FKBP52 binding to TRPC1. Also provided are methods for identifying an inhibitor of an FKBP52-TRPC1 signaling pathway by contacting a cell expressing TRPC1 and FKBP52 with a test agent and detecting a change in agonist-induced calcium flux of TRPC1. Further provided are methods of enhancing axonal outgrowth by inhibiting the activity of FKBP52 in a neuronal growth cone, and methods of enhancing axonal regeneration in a subject in need thereof by administering an agent that inhibits the activity of FKBP52. | 2011-07-14 |
20110171231 | ANTI-PlGF ANTIBODIES AND METHODS USING SAME - The invention provides anti-PlGF antibodies and methods of using the same. | 2011-07-14 |
20110171232 | METHODS OF TREATING AUTOIMMUNE DISEASES CAUSED BY SMALL INTESTINAL BACTERIAL OVERGROWTH - Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases. | 2011-07-14 |
20110171233 | Antibodies Against Human Cytomegalovirus (HCMV) - The present invention provides novel antibodies sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections. | 2011-07-14 |
20110171234 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 2011-07-14 |